Today is the day! The @Nature #COVIDconsensus paper is now live at https://t.co/RxSFPkZUOb. All of our recommendations are 100% within human control and we need your help to spread the message to end #COVID19 as a #publichealth threat! #CovidTwitter

True conversation today with a colleague: He: “I wrote a paper using ChatGPT. I realized both reviewers used ChatGPT, and I’m pretty sure the rejection letter was also written by ChatGPT. Ramon, what should I do next?” Me: “Ask ChatGPT.”

We're thrilled to be in the first @LancetGastroHep issue of 2026 with the global MASLD #BestBuys study: https://t.co/UR40Ke9dWs #LiverTwitter

Indicator conditions: Should we test everyone living with diabetes type 2 for MASH? "Cost-Effectiveness of MASH Diagnosis and Management Approaches Among Those With Type 2 Diabetes" https://t.co/7ySaLZR2j2 #LiverTwitter @LuisAntonioDiaz @AlinaAllenMD @AlkhouriNaim

🚨Don't miss the 4th #LIVERAIM webinar! Early detection of Chronic Liver Disease in primay care: real-world perspectives 🗓️Tomorrow, 16:15-17:CET register here: https://t.co/CBedgBRcnM @IHIEurope @EASLedu @WoncaWorld

Congratulations on 76 years of never having to grow up.  Happy Birthday!

Millions of people worldwide do not have access and/or cannot afford NCD care. The current gap is unacceptable. 📢Following #HLM4, we need to keep the pressure on to make a real difference for the lives of people living with NCDs. 📚Check out our new pocket guide aimed at

I support the Danish proposal for a free (no direct cost to the consumer) annual dentist visit for adults. #TeethMatter https://t.co/uI6jyMyboI

So excited to see this out. A fantastic patient-centric, physician-friendly approach to all things nutrition in MASLD. Led by @KatrinaPekarska with incredible co-authors @josewillemse @stumcp @JVLazarus @JonathanStineMD //fg.bmj.com/content/early/2025/11/30/flgastro-2025-103183

2 billion people face financial hardship paying for health care, often instead of food, education or housing. That’s 1/4 of the world’s population! This #UHCDay (🗓️12 December), we call on leaders to invest in #UHC to protect the right to health. Join the @UHC2030 campaign here

New @Medscape coverage highlights findings from the #VHCOMSAVAC project, led by Camila Picchio (#ISGlobal): 👉🏽 Taking #HBV vaccination directly into migrant communities can boost first-dose uptake to nearly 90%. A promising model to reduce #hepatitis B and future liver cancer

📑 Awareness of #MASLD in 4 major cities in the United States 🇺🇸 is LOW‼️ https://t.co/Oycis0bEuq

An honor to deliver the opening remarks at the @AACEMENA Conference in Dubai—bringing together leading endocrinologists from across the region to advance endocrine and metabolic care. #AACEMENA2025 @TheAACE

Proud to share our article in @JAMANetworkOpen Across 12 countries, we evaluated 14 strategies for MASH with T2D 🔹 Screening + ILIs are cost-effective everywhere 🔹 ILIs + semaglutide or resmetirom work in most settings @leireagi09 @JVLazarus @LuisAntonioDiaz #ActOnNCDs

Congratulations to @JVLazarus , @ZobairYounossi and Dr. Kenneth Cusi for being featured as experts in the @JAMA_current article on MASLD—The Chronic Liver Disease That Affects Tens of Millions of US Adults but Flies Under the Radar. https://t.co/hNebnfCoSE

Long term follow up of the MATCH trial - congrats ⁦@brennap9⁩ #tlm25 ⁦@AASLDtweets⁩ ⁦⁦@JAFallowfield⁩ ⁦@JVLazarus⁩ ⁦@ResolutionTx⁩

Congratulations to Dr @LuisAntonioDiaz for receiving the 2025 Early Career Investigator Award in Clinical/Translational Science. So proud of you! Very well deserved for your leadership in changing the life for so many patients #TLM25 @AASLDtweets @AASLDFoundation @AASLDPresident

Honored that our #MASLD screening cost study is the cover feature in @LiverInt. We compared screening costs across Brazil, Germany, Japan, Saudi Arabia, Spain, and the US, introducing a new approach that factors in screening all people living with diabetes.

🏆 ¡Enhorabuena al Public Health Liver Group de #ISGlobal! El proyecto #VHCOMSAVAC ha recibido el Premio a la Prevención de Enfermedades Infecciosas por su labor en la detección, prevención y atención frente a la #hepatitis viral.👏 #SaludGlobal #NoHep cc @JVLazarus @iCERCA

Proud to share our new study in @LiverInt, featured as the cover story. We analyzed MASLD/MASH screening costs across six countries (Brazil, Germany, Japan, Saudi Arabia, Spain, and the US) using a novel approach that includes screening all individuals with diabetes. Grateful to

Mid-career academics have non-stop invitations. If you’re not good at saying “NO” (like I wasn’t), your quality and peace of mind suffer. My advice: keep a small notebook with two columns: YES ✅ (accepted) and NO 🚫 (declined). Before replying, open it and make a wise decision.